Oleic Acid ( DrugBank: Oleic Acid )


2 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1
299Cystic fibrosis1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00638196
(ClinicalTrials.gov)
March 200810/3/2008Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MSPhase II Study of Linoleic Acid in Relapsing Multiple SclerosisMultiple SclerosisDrug: Linoleic Acid/Oleic AcidUniversity of RochesterNULLTerminated18 Years70 YearsBoth9Phase 1United States

299. Cystic fibrosis


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04531410
(ClinicalTrials.gov)
July 1, 202118/8/2020NETwork of Linoleic Acid Supplementation in Cystic FibrosisDouble-blind Randomized Controlled Study of Linoleic Acid Supplementation for 1 Year in Patients With Cystic Fibrosis - Influence on Clinical Status and MetabolismCystic FibrosisDietary Supplement: linoleic acid supplementation;Dietary Supplement: oleic acid supplementationKarolinska InstitutetEuropean Society of Pediatric Gastroenterology, Hepatology and NutritionEnrolling by invitation5 Years15 YearsAll90N/AItaly;Norway;Poland;Sweden